Premium
Does neoadjuvant therapy for pancreatic head adenocarcinoma increase postoperative morbidity? A systematic review of the literature with meta‐analysis
Author(s) -
Araujo Raphael L. C.,
Silva Raphael O.,
Pádua Souza Cristiano,
Milani Jean M.,
Huguet Florence,
Rezende Ana C.,
Gaujoux Sebastien
Publication year - 2020
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25851
Subject(s) - medicine , meta analysis , neoadjuvant therapy , pancreatic cancer , pancreatic fistula , pancreatic head , surgery , adenocarcinoma , resection , oncology , cancer , pancreas , breast cancer
Neoadjuvant treatment (NT) for pancreatic head cancer may allow some patients to undergo curative resection, but its impact on postoperative complications remains unclear. A systematic review and meta‐analysis were performed to compare overall postoperative morbidity, pancreatic fistula, and mortality between patients who underwent upfront surgery and those who underwent neoadjuvant therapy first. Forty‐five studies with 3359 patients were included. No significant differences in morbidity and mortality rates associated with NT for pancreatic head cancer were detected in this study.